Skip to main content
. Author manuscript; available in PMC: 2022 Jun 8.
Published in final edited form as: Leuk Lymphoma. 2020 Jul 20;61(11):2630–2637. doi: 10.1080/10428194.2020.1783443

Table 1.

Patient demographic, clinical, and treatment characteristics.

Total (N = 141)
Characteristica n %

Age, years
 Mean (SD) 35.6 (7.8)
 Median (range) 35.0 (19.0–69.0)
Sex
 Men 85 60.3%
 Women 56 39.7%
Region
 Northeast 52 36.9%
 Midwest 23 16.3%
 South 48 34.0%
 West 18 12.8%
Community
 City 64 45.4%
 Suburb 67 47.5%
 Small town or village 10 7.1%
 Did not disclose 0 0
Education
 Below high school or equivalent 0 0
 High school or equivalent 10 7.1%
 Technical school/training 10 7.1%
 Some college, university, or other post-secondary education 30 21.3%
 College, university, or other post-secondary education 64 45.4%
 Graduate degree 27 19.1%
Stage of HL at diagnosis
 Early/Intermediate (stage I or II) 94 66.7%
 Advanced (stage III or IV) 47 33.3%
Time since HL diagnosis, years
 Mean (SD) 4.1 (9.4)
 Median (range) 1.1 (0.0–39.1)
Source of information on treatment for HL b
 Oncologist 118 83.7%
 Nurse/other HCP 110 78.0%
 Family/friends 68 48.2%
 Other patients/patient advocacy organization 45 31.9%
 Internet/television/magazine 89 63.1%
 None 3 2.1%
Treatment status
 No treatment decision made 8 5.7%
 Decision made, not yet started treatment 32 22.7%
 Currently on treatment 59 41.8%
 Completed treatment 42 29.8%

SD: standard deviations; HL: Hodgkin lymphoma; HCP: healthcare professional/provider.

a

n, % except where otherwise indicated.

b

Percentages may sum to more than 100%.